158 related articles for article (PubMed ID: 24243516)
1. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
Haji Ali Afzali H; Gray J; Beilby J; Holton C; Karnon J
Appl Health Econ Health Policy; 2013 Dec; 11(6):661-70. PubMed ID: 24243516
[TBL] [Abstract][Full Text] [Related]
2. A risk adjusted cost-effectiveness analysis of alternative models of nurse involvement in obesity management in primary care.
Karnon J; Ali Afzali HH; Gray J; Holton C; Banham D; Beilby J
Obesity (Silver Spring); 2013 Mar; 21(3):472-9. PubMed ID: 23592655
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
5. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
6. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
Colagiuri S; Walker AE
Health Aff (Millwood); 2008; 27(1):256-68. PubMed ID: 18180502
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
8. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes.
Schouten LM; Niessen LW; van de Pas JW; Grol RP; Hulscher ME
Med Care; 2010 Oct; 48(10):884-91. PubMed ID: 20808258
[TBL] [Abstract][Full Text] [Related]
10. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
11. Report on financing the new model of family medicine.
Spann SJ;
Ann Fam Med; 2004 Dec; 2 Suppl 3(Suppl 3):S1-21. PubMed ID: 15654084
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
13. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
15. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
16. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
17. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
[TBL] [Abstract][Full Text] [Related]
18. Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany.
Liebl A; Seitz L; Palmer AJ
Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):517-22. PubMed ID: 25148263
[TBL] [Abstract][Full Text] [Related]
19. Identifying organisational principles and management practices important to the quality of health care services for chronic conditions.
Frølich A
Dan Med J; 2012 Feb; 59(2):B4387. PubMed ID: 22293057
[TBL] [Abstract][Full Text] [Related]
20. Triggering factors of primary care costs in the years following type 2 diabetes diagnosis in Mexico.
Castro-Ríos A; Nevárez-Sida A; Tiro-Sánchez MT; Wacher-Rodarte N
Arch Med Res; 2014 Jul; 45(5):400-8. PubMed ID: 24825741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
